References
- Bendotti C, Carri MT. Lessons from models of SOD1-linked familial ALS. Trends Mol Med. 2004; 10: 393–400
- Carri MT, Grignaschi G, Bendotti C. Targets in ALS: designing multidrug therapies. Trends Pharmacol Sci. 2006; 27: 267–73
- Fornai F, Longone P, Cafaro L, Kastsiuchenka O, Ferrucci M, Manca ML, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2008; 105: 2052–7
- Gurney ME. Transgenic mouse model of amyotrophic lateral sclerosis. N Engl J Med. 1994; 331: 1721–2
- Bolann BJ, Rahil-Khazen R, Henriksen H, Isrenn R, Ulvik RJ. Evaluation of methods for trace-element determination with emphasis on their usability in the clinical routine laboratory. Scand J Clin Lab Invest. 2007; 67: 353–66
- Grotti M. Improving the analytical performances of inductively coupled plasma optical emission spectrometry by multivariate analysis techniques. Ann Chim. 2004; 94: 1–15
- Morimoto N, Nagai M, Ohta Y, Miyazaki K, Kurata T, Morimoto M, et al. Increased autophagy in transgenic mice with a G93A mutant SOD1 gene. Brain Res. 2007; 1167: 112–7
- Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK. Enhancement of hippocampal neurogenesis by lithium. J Neurochem. 2000; 75: 1729–34
- Wada A, Yokoo H, Yanagita T, Kobayashi H. Lithium: potential therapeutics against acute brain injuries and chronic neurodegenerative diseases. J Pharmacol Sci. 2005; 99: 307–21
- Nciri R, Allagui MS, Croute F, Vincent C, Elfeki A. Effects of low doses of lithium carbonate injected into mice. Functional changes in kidney seem to be related to the oxidative status. C R Biol. 2008; 331: 23–31
- Feng HL, Leng Y, Ma CH, Zhang J, Ren M, Chuang DM. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience. 2008; 155: 567–72
- Shin JH, Cho SI, Lim HR, Lee JK, Lee YA, Noh JS, et al. Concurrent administration of Neu2000 and lithium produces marked improvement of motor neuron survival, motor function, and mortality in a mouse model of amyotrophic lateral sclerosis. Mol Pharmacol 20070; 71: 965–75
- Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis. 2007; 26: 1–13
- Cheroni C, Marino M, Tortarolo M, Veglianese P, de Biasi S, Fontana E, et al. Functional alterations of the ubiquitin proteasome system in motor neurons of a mouse model of familial amyotrophic lateral sclerosis. Hum Mol Genet. 2009; 18: 82–96
- Heiman-Patterson TD, Deitch JS, Blankenhorn EP, Erwin KL, Perreault MJ, Alexander BK, et al. Background and gender effects on survival in the TgN(SOD1G93A )1Gur mouse model of ALS. J Neurol Sci. 2005; 236: 1–7
- Schwalenstocker B, Danzeisen R, Ludolph AC. Copaxone treatment in a mouse model of ALS: effect of gender and genetic background. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004; 5(Suppl 2)9
- Mahoney DJ, Rodriguez C, Devries M, Yasuda N, Tarnopolsky MA. Effects of high-intensity endurance exercise training in the G93A mouse model of amyotrophic lateral sclerosis. Muscle Nerve. 2004; 29: 656–62